Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 294,282 | 179,278 | 116,882 | 120,242 | 149,236 |
| Cost of Goods | 19,621 | 18,647 | 7,110 | 1,749 | 1,083 |
| Gross Profit | 274,661 | 160,631 | 109,772 | 118,493 | 148,153 |
| Operating Expenses | 149,816 | 137,086 | 130,373 | 174,792 | 160,732 |
| Operating Income | 125,466 | 24,192 | -20,491 | -55,550 | -12,496 |
| Interest Expense | 7,320 | 7,918 | 6,872 | 3,707 | 4,860 |
| Other Income | 3,681 | 2,092 | 2,272 | 684 | 47 |
| Pre-tax Income | 121,827 | 18,366 | -25,091 | -58,573 | -17,309 |
| Income Tax | -245,197 | 881 | N/A | N/A | 605 |
| Net Income Continuous | 367,024 | 17,485 | -25,091 | -58,573 | -17,914 |
| Net Income | $367,024 | $17,485 | $-25,091 | $-58,573 | $-17,914 |
| EPS Basic Total Ops | 20.40 | 0.99 | -1.44 | -3.44 | -1.10 |
| EPS Basic Continuous Ops | 20.41 | 0.99 | -1.44 | -3.44 | -1.05 |
| EPS Diluted Total Ops | 19.48 | 0.99 | -1.44 | -3.44 | -1.10 |
| EPS Diluted Continuous Ops | 19.48 | 0.99 | -1.44 | -3.44 | -1.05 |
| EPS Diluted Before Non-Recurring Items | 6.43 | 0.99 | -1.40 | -3.40 | -1.10 |
| EBITDA(a) | $126,731 | $25,711 | $-19,732 | $-54,615 | $-11,047 |